Last 12 months
Inside the activity.
0 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2020 Filed Mar 6, 2020 01:14 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
SaleCommon Stock | 98,093 | $30.86 | $3,027,149.98 |
DisclosureSEC source: 0001077183-20-000047 · wf-form4_158345723213644.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,640 Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 01:14 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Exercise / conversionCommon Stock | 96,167 | $8.03 | $772,221.01 |
DisclosureSEC source: 0001077183-20-000047 · wf-form4_158345723213644.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:10 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantCommon Stock · Derivative | 56,271 | $28.33 Strike: $28.33 | $1,594,157.43 |
DisclosureSEC source: 0001077183-20-000035 · wf-form4_158328420295607.xml · derivative · entry 6 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,271 Underlying: Common Stock · 56,271 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:10 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
GrantCommon Stock | 8,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000035 · wf-form4_158328420295607.xml · nonDerivative · entry 2 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,566 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:26 UTC |
Bonello WilliamPresident, Informatics
|
GrantCommon Stock · Derivative | 37,514 | $28.33 Strike: $28.33 | $1,062,771.62 |
DisclosureSEC source: 0001077183-20-000043 · wf-form4_158328516474870.xml · derivative · entry 6 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,514 Underlying: Common Stock · 37,514 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. Bonello was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:26 UTC |
Bonello WilliamPresident, Informatics
|
GrantCommon Stock | 5,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000043 · wf-form4_158328516474870.xml · nonDerivative · entry 2 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,060 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:20 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantCommon Stock · Derivative | 15,006 | $28.33 Strike: $28.33 | $425,119.98 |
DisclosureSEC source: 0001077183-20-000041 · wf-form4_158328479579697.xml · derivative · entry 6 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,006 Underlying: Common Stock · 15,006 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Ms. Balliet was granted 15,006 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:20 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
GrantCommon Stock | 2,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000041 · wf-form4_158328479579697.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,980 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:16 UTC |
Pedulla Denise EGeneral Counsel
|
GrantCommon Stock · Derivative | 18,757 | $28.33 Strike: $28.33 | $531,385.81 |
DisclosureSEC source: 0001077183-20-000039 · wf-form4_158328455458567.xml · derivative · entry 6 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,757 Underlying: Common Stock · 18,757 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Ms. Pedulla was granted 18,757 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:16 UTC |
Pedulla Denise EGeneral Counsel
|
GrantCommon Stock | 2,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000039 · wf-form4_158328455458567.xml · nonDerivative · entry 1 Pedulla Denise E · CIK 0001804602 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,988 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:13 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
GrantCommon Stock · Derivative | 48,768 | $28.33 Strike: $28.33 | $1,381,597.44 |
DisclosureSEC source: 0001077183-20-000037 · wf-form4_158328436965681.xml · derivative · entry 7 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,768 Underlying: Common Stock · 48,768 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:13 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
GrantCommon Stock | 7,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000037 · wf-form4_158328436965681.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,402 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:06 UTC |
Weiss Lawrence MartinChief Medical Officer
|
GrantCommon Stock · Derivative | 37,514 | $28.33 Strike: $28.33 | $1,062,771.62 |
DisclosureSEC source: 0001077183-20-000033 · wf-form4_158328396163882.xml · derivative · entry 4 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,514 Underlying: Common Stock · 37,514 shares Expires 2027-03-02 F3 · derivative.exercise_date: On March 2, 2020, Dr. Weiss was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:06 UTC |
Weiss Lawrence MartinChief Medical Officer
|
GrantCommon Stock | 5,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000033 · wf-form4_158328396163882.xml · nonDerivative · entry 1 Weiss Lawrence Martin · CIK 0001761625 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,717 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:03 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
GrantCommon Stock · Derivative | 225,084 | $28.33 Strike: $28.33 | $6,376,629.72 |
DisclosureSEC source: 0001077183-20-000032 · wf-form4_158328381578221.xml · derivative · entry 7 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,084 Underlying: Common Stock · 225,084 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Mr. VanOort was granted 225,084 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:03 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
GrantCommon Stock | 34,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000032 · wf-form4_158328381578221.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,316,073 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:00 UTC |
McKenzie Kathryn BChief Financial Officer
|
GrantCommon Stock · Derivative | 37,514 | $28.33 Strike: $28.33 | $1,062,771.62 |
DisclosureSEC source: 0001077183-20-000030 · wf-form4_158328361900393.xml · derivative · entry 6 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,514 Underlying: Common Stock · 37,514 shares Expires 2027-03-02 F5 · derivative.exercise_date: On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 01:00 UTC |
McKenzie Kathryn BChief Financial Officer
|
GrantCommon Stock | 5,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000030 · wf-form4_158328361900393.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:17 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 20,000 | $28.24 | $564,800.00 |
DisclosureSEC source: 0001077183-20-000045 · wf-form4_158336742702577.xml · nonDerivative · entry 4 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Jones Network, LP Disclosed balance after: 30,476 Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:17 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 2,300 | $28.24 | $64,952.00 |
DisclosureSEC source: 0001077183-20-000045 · wf-form4_158336742702577.xml · nonDerivative · entry 3 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned in IRA, custodian accounts, and trusts for the family of Steven Jones Disclosed balance after: 40,757 Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:17 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 25,000 | $28.48 | $712,000.00 |
DisclosureSEC source: 0001077183-20-000045 · wf-form4_158336742702577.xml · nonDerivative · entry 2 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By self as Trustee for Steven and Carisa Jones 401k and Trust Disclosed balance after: 125,000 Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:17 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 250,000 | $28.85 | $7,212,500.00 |
DisclosureSEC source: 0001077183-20-000045 · wf-form4_158336742702577.xml · nonDerivative · entry 1 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 1,375,000 F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:10 UTC |
SHOVLIN ROBERT J.President, Clinical Services
|
Tax withholdingCommon Stock | 810 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000035 · wf-form4_158328420295607.xml · nonDerivative · entry 1 SHOVLIN ROBERT J. · CIK 0001621453 · President, Clinical Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,830 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:26 UTC |
Bonello WilliamPresident, Informatics
|
Tax withholdingCommon Stock | 499 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000043 · wf-form4_158328516474870.xml · nonDerivative · entry 1 Bonello William · CIK 0001454941 · President, Informatics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,236 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:20 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Tax withholdingCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000041 · wf-form4_158328479579697.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,650 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:03 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000032 · wf-form4_158328381578221.xml · nonDerivative · entry 2 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,281,128 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 01:00 UTC |
McKenzie Kathryn BChief Financial Officer
|
Tax withholdingCommon Stock | 168 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-20-000030 · wf-form4_158328361900393.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105 F1 · shares: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:45 UTC |
JONES STEVEN CDirector
|
OtherStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-20-000003 · wf-form4_157800868815371.xml · derivative · entry 10 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2021-04-20 F2 · kind: On December 30, 2019, Mr. Jones transferred this option to Aspen Select Opportunity Fund, LP as part of estate planning activities. F4 · derivative.exercise_date: On April 20, 2016, Mr. Jones was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:45 UTC |
JONES STEVEN CDirector
|
OtherStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-20-000003 · wf-form4_157800868815371.xml · derivative · entry 9 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2021-04-20 F2 · kind: On December 30, 2019, Mr. Jones transferred this option to Aspen Select Opportunity Fund, LP as part of estate planning activities. F4 · derivative.exercise_date: On April 20, 2016, Mr. Jones was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:45 UTC |
JONES STEVEN CDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001077183-20-000003 · wf-form4_157800868815371.xml · derivative · entry 8 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 125,000 Underlying: Common Stock · 100,000 shares Expires 2020-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 4, 2015, Mr. Jones was granted 225,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:45 UTC |
JONES STEVEN CDirector
|
OtherStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001077183-20-000003 · wf-form4_157800868815371.xml · derivative · entry 7 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2020-05-04 F2 · kind: On December 30, 2019, Mr. Jones transferred this option to Aspen Select Opportunity Fund, LP as part of estate planning activities. F3 · derivative.exercise_date: On May 4, 2015, Mr. Jones was granted 225,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:45 UTC |
JONES STEVEN CDirector
|
OtherStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001077183-20-000003 · wf-form4_157800868815371.xml · derivative · entry 6 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2020-05-04 F2 · kind: On December 30, 2019, Mr. Jones transferred this option to Aspen Select Opportunity Fund, LP as part of estate planning activities. F3 · derivative.exercise_date: On May 4, 2015, Mr. Jones was granted 225,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 23:45 UTC |
JONES STEVEN CDirector
|
Exercise / conversionCommon Stock | 100,000 | $4.78 | $478,000.00 |
DisclosureSEC source: 0001077183-20-000003 · wf-form4_157800868815371.xml · nonDerivative · entry 5 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 1,625,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:28 UTC |
McKenzie Kathryn BChief Accounting Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-19-000230 · wf-form4_157619689019440.xml · derivative · entry 3 McKenzie Kathryn B · CIK 0001720001 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 8,000 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:28 UTC |
McKenzie Kathryn BChief Accounting Officer
|
SaleCommon Stock | 8,000 | $26.37 | $210,960.00 |
DisclosureSEC source: 0001077183-19-000230 · wf-form4_157619689019440.xml · nonDerivative · entry 2 McKenzie Kathryn B · CIK 0001720001 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273 Read SEC document |
| December 10, 2019 Filed Dec 13, 2019 00:28 UTC |
McKenzie Kathryn BChief Accounting Officer
|
Exercise / conversionCommon Stock | 8,000 | $8.03 | $64,240.00 |
DisclosureSEC source: 0001077183-19-000230 · wf-form4_157619689019440.xml · nonDerivative · entry 1 McKenzie Kathryn B · CIK 0001720001 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 22:35 UTC |
JONES STEVEN CDirector
|
GiftCommon Stock | 50,000 | $24.53 | $1,226,500.00 |
DisclosureSEC source: 0001077183-19-000220 · wf-form4_157446213009752.xml · nonDerivative · entry 5 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,234 Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 22:35 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 23,162 | $24.27 | $562,141.74 |
DisclosureSEC source: 0001077183-19-000220 · wf-form4_157446213009752.xml · nonDerivative · entry 4 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 1,525,000 F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 22:35 UTC |
JONES STEVEN CDirector
|
SaleCommon Stock | 128,068 | $24.35 | $3,118,455.80 |
DisclosureSEC source: 0001077183-19-000220 · wf-form4_157446213009752.xml · nonDerivative · entry 3 JONES STEVEN C · CIK 0001518732 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aspen Select Opportunity Fund Disclosed balance after: 1,548,162 F1 · ownership.nature: Aspen Select Opportunity Fund is a private investment fund of which Aspen Capital Group, LLC is the sole general partner. Mr. Jones is a Managing Member of Aspen Capital Group, LLC. Mr. Jones disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 22:32 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
SaleCommon Stock | 187,500 | $24.08 | $4,515,000.00 |
DisclosureSEC source: 0001077183-19-000217 · wf-form4_157437553229846.xml · nonDerivative · entry 3 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Conundrum Capital Partners Disclosed balance after: 0 F1 · ownership.nature: Conundrum Capital Partners, LLC is a limited liability partnership 50% owned by Mr. VanOort. Mr. VanOort is a managing partner of Conundrum Capital Partners, LLC Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 17:30 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 166 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001077183-19-000212 · wf-form4_157409823242326.xml · derivative · entry 5 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,334 Underlying: Common Stock · 166 shares Expires 2023-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On February 26, 2018, Jennifer Balliet was granted 72,500 stock options which vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 17:30 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,667 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001077183-19-000212 · wf-form4_157409823242326.xml · derivative · entry 4 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 6,667 shares Expires 2022-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 28, 2017, Jennifer Balliet was granted 60,000 stock options which vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 17:30 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
SaleCommon Stock | 6,833 | $23.45 | $160,233.85 |
DisclosureSEC source: 0001077183-19-000212 · wf-form4_157409823242326.xml · nonDerivative · entry 3 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,862 Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 17:30 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 166 | $8.03 | $1,332.98 |
DisclosureSEC source: 0001077183-19-000212 · wf-form4_157409823242326.xml · nonDerivative · entry 2 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 17:30 UTC |
BALLIET JENNIFERVP and Chief Culture Officer
|
Exercise / conversionCommon Stock | 6,667 | $7.52 | $50,135.84 |
DisclosureSEC source: 0001077183-19-000212 · wf-form4_157409823242326.xml · nonDerivative · entry 1 BALLIET JENNIFER · CIK 0001640500 · VP and Chief Culture Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:11 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 44,444 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000210 · wf-form4_157376945753382.xml · derivative · entry 3 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 44,444 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On April 20, 2016, Mr. Cardoza was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:11 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
SaleCommon Stock | 19,444 | $23.15 | $450,128.60 |
DisclosureSEC source: 0001077183-19-000210 · wf-form4_157376945753382.xml · nonDerivative · entry 2 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,831 Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:11 UTC |
CARDOZA GEORGEPresident, Pharma Services
|
Exercise / conversionCommon Stock | 44,444 | $7.15 | $317,774.60 |
DisclosureSEC source: 0001077183-19-000210 · wf-form4_157376945753382.xml · nonDerivative · entry 1 CARDOZA GEORGE · CIK 0001518734 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 22:43 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
Exercise / conversionStock Option (Right to Buy · Derivative | 472,527 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001077183-19-000208 · wf-form4_157368500878449.xml · derivative · entry 6 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 472,527 shares Expires 2021-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 20, 2016, Mr. VanOort was granted 472,527 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 22:43 UTC |
VAN OORT DOUGLAS MDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 205,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-19-000208 · wf-form4_157368500878449.xml · nonDerivative · entry 5 VAN OORT DOUGLAS M · CIK 0001518733 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,277,391 F4 · shares: Shares withheld by NeoGenomics, Inc. for the cost of exercise and to satisfy the tax obligations in connection with the November 8, 2019 exercise of stock options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.